Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model.
Cansfield AD, Ladduwahetty T, Sunose M, Ellard K, Lynch R, Newton AL, Lewis A, Bennett G, Zinn N, Thomson DW, Rüger AJ, Feutrill JT, Rausch O, Watt AP, Bergamini G. Cansfield AD, et al. Among authors: ladduwahetty t. ACS Med Chem Lett. 2016 Jun 10;7(8):768-73. doi: 10.1021/acsmedchemlett.6b00149. eCollection 2016 Aug 11. ACS Med Chem Lett. 2016. PMID: 27563401 Free PMC article.
Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease.
Ladduwahetty T, Lee MR, Maillard MC, Cachope R, Todd D, Barnes M, Beaumont V, Chauhan A, Gallati C, Haughan AF, Kempf G, Luckhurst CA, Matthews K, McAllister G, Mitchell P, Patel H, Rose M, Saville-Stones E, Steinbacher S, Stott AJ, Thatcher E, Tierney J, Urbonas L, Munoz-Sanjuan I, Dominguez C. Ladduwahetty T, et al. J Med Chem. 2022 Jul 28;65(14):9819-9845. doi: 10.1021/acs.jmedchem.2c00474. Epub 2022 Jul 11. J Med Chem. 2022. PMID: 35816678
Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology.
Macabuag N, Esmieu W, Breccia P, Jarvis R, Blackaby W, Lazari O, Urbonas L, Eznarriaga M, Williams R, Strijbosch A, Van de Bospoort R, Matthews K, Clissold C, Ladduwahetty T, Vater H, Heaphy P, Stafford DG, Wang HJ, Mangette JE, McAllister G, Beaumont V, Vogt TF, Wilkinson HA, Doherty EM, Dominguez C. Macabuag N, et al. Among authors: ladduwahetty t. J Med Chem. 2022 Sep 22;65(18):12445-12459. doi: 10.1021/acs.jmedchem.2c01149. Epub 2022 Sep 13. J Med Chem. 2022. PMID: 36098485 Free PMC article.
Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's Disease.
Liu L, Malagu K, Haughan AF, Khetarpal V, Stott AJ, Esmieu W, Vater HD, Webster SJ, Van de Poël AJ, Clissold C, Cosgrove B, Sutton B, Spencer JA, Breccia P, Gancia E, Bonomo S, Ladduwahetty T, Lazari O, Patel H, Atton HC, Clifton S, Mota DM, Magnani D, O'Neill A, Stebbeds M, Macabuag N, Todd D, Herva ME, Mitchell P, Visser M, Compte Sancerni S, Grand Moursel L, da Silva M, Kritikou E, Heikkinen TT, Bolkvadze T, Fodale V, Spadafora D, Daldin M, Bresciani A, Mangette JE, Doherty EM, Lee MR, Herbst T, Monteagudo E, Macdonald D, Plotnikov NV, Chambers M, McAllister G, Muňoz-Sanjuan I, Dominguez C. Liu L, et al. Among authors: ladduwahetty t. J Med Chem. 2023 Sep 28;66(18):13205-13246. doi: 10.1021/acs.jmedchem.3c01173. Epub 2023 Sep 15. J Med Chem. 2023. PMID: 37712656
Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.
Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod AM, Ladduwahetty T, Keown L, Swain C, Baker R, Cascieri M, Ber E, Metzger J, MacIntyre DE, Hill RG, Hargreaves RJ. Tattersall FD, et al. Among authors: ladduwahetty t. Neuropharmacology. 1996;35(8):1121-9. doi: 10.1016/s0028-3908(96)00020-2. Neuropharmacology. 1996. PMID: 9121615
An efficient protocol for the preparation of primary alcohols bearing a beta-chiral center via an oxazolidinone auxiliary mediated resolution, and application to the synthesis of 4,4-disubstituted piperidine substance P antagonists.
Lewis RT, Ladduwahetty T, Merchant KJ, Keown LE, Hitzel L, Verrier H, Stevenson GI, MacLeod AM. Lewis RT, et al. Among authors: ladduwahetty t. J Org Chem. 2000 Apr 21;65(8):2615-8. doi: 10.1021/jo9918246. J Org Chem. 2000. PMID: 10789488 No abstract available.
4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia.
Fish LR, Gilligan MT, Humphries AC, Ivarsson M, Ladduwahetty T, Merchant KJ, O'Connor D, Patel S, Philipps E, Vargas HM, Hutson PH, MacLeod AM. Fish LR, et al. Among authors: ladduwahetty t. Bioorg Med Chem Lett. 2005 Aug 15;15(16):3665-9. doi: 10.1016/j.bmcl.2005.05.104. Bioorg Med Chem Lett. 2005. PMID: 15993598
A new class of selective, non-basic 5-HT2A receptor antagonists.
Ladduwahetty T, Boase AL, Mitchinson A, Quin C, Patel S, Chapman K, MacLeod AM. Ladduwahetty T, et al. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3201-4. doi: 10.1016/j.bmcl.2006.03.050. Epub 2006 May 2. Bioorg Med Chem Lett. 2006. PMID: 16632354
15 results